Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

PATRICIA L LUGAR

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1376741967
CMS profile
1171013
Location
DURHAM, NC

General Payments · PY2018–2024

$140,270.25

  • Reported across 141 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$11,215.38

13 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Blueprint Medicines Corporation $6,664.69 10
CSL Behring $4,290.00 1
BioMarin Pharmaceutical Inc. $229.29 1
BioCryst US Sales Co., LLC $31.40 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $18,108.85 33
PY2019 $8,830.53 21
PY2020 $11,530.34 16
PY2021 $9,945.44 8
PY2022 $35,035.62 19
PY2023 $45,604.09 31
PY2024 $11,215.38 13

Payment records · PY2024 (13)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
BioCryst US Sales Co., LLC $31.40 02/23/2024 Food and Beverage Undisputed 01/23/2026 1117480434 CMS
BioMarin Pharmaceutical Inc. $229.29 02/22/2024 Food and Beverage Undisputed 01/23/2026 1127059773 CMS
Blueprint Medicines Corporation $2,650.00 02/21/2024 Honoraria Undisputed 01/23/2026 1147441102 CMS
Blueprint Medicines Corporation $80.00 02/21/2024 Food and Beverage Undisputed 01/23/2026 1147441104 CMS
Blueprint Medicines Corporation $108.59 02/21/2024 Food and Beverage Undisputed 01/23/2026 1147441106 CMS
Blueprint Medicines Corporation $134.40 02/25/2024 Food and Beverage Undisputed 01/23/2026 1147441100 CMS
Blueprint Medicines Corporation $1,908.00 03/15/2024 Consulting Fee Undisputed 01/23/2026 1147441070 CMS
Blueprint Medicines Corporation $39.44 03/15/2024 Food and Beverage Undisputed 01/23/2026 1147441072 CMS
Blueprint Medicines Corporation $13.85 03/15/2024 Food and Beverage Undisputed 01/23/2026 1147441074 CMS
Blueprint Medicines Corporation $105.41 10/25/2024 Food and Beverage Undisputed 01/23/2026 1147441110 CMS
Blueprint Medicines Corporation $650.00 11/05/2024 Consulting Fee Undisputed 01/23/2026 1147441118 CMS
Blueprint Medicines Corporation $975.00 11/05/2024 Consulting Fee Undisputed 01/23/2026 1147441120 CMS
CSL Behring $4,290.00 12/06/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1134613011 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.